Leukotrienes in breath condensate in patients with asthma and COPD;Vyšentření leukotrienů v kondenzátu vydechovaného vzduchu u nemocných s astmatem a CHOPN

Alergie

Volumn 4, Issue 1, 2002, Pages 15-20

  Čáp, Petr ^a   Pehal, František ^a   Petrů, Vít ^a   Musil, Jaromír ^a   Malý, Marek ^a  

^a NA HOMOLCE HOSPITAL   (Czech Republic)

Author keywords

Breath condensate; Cysteinyl leukotrienes; Leukotrienes B4

Indexed keywords

LEUKOTRIENE B4; LEUKOTRIENE DERIVATIVE; PEPTIDOLEUKOTRIENE;

ARTICLE; ASTHMA; BREATH ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; GAS CHROMATOGRAPHY; HUMAN; LOWER RESPIRATORY TRACT; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PILOT STUDY;

EID: 0036242657     PISSN: 12123536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Determination of sulfidopeptide leukotrienes in biological fluids by gas chromatography/mass spectrometry
2. Worldwide clinical experience with the first marketed leukotriene receptor antagonist
3. Pranlukast, novel leukotriene receptor antagonist: Results of the first European, placebo controlled, multicentre clinical study in asthma
4. Biochemistry and physiology of the leukotrienes
5. Leukotrienes in breathing condensate released during bronchial challenge test
6. Leukotrienes in breathinig condensate released during bronchial challenge test with allergen
7. Leukotrienes B4 in breathing condensate of patients with bronchopulmonary diseases and in normals
8. Breth condensate as a method of non invasive assessment of inflammation mediators from the lower airways
9. The role of leukotrienes in asthma and allergic rhinitis
10. Asthma and Leukotrienes: Antileukotrienes as novel antiasthmatic drugs
11. A specific LTD4/LTE4 receptor antagonist improves pulmonary function in patients with mild chronic asthma
12. Kondenzát vydechovaného vzduchu a možnosti jeho vyšetřeni
13. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics
14. Nitrotyrosine ans cysteinyl leukotrienes in breath condensate are increased after withdrawal of steroid treatment in patients with the asthma
15. The effect of inhibition of 5-lipoxygenase by Zileuton in mild-to-moderate asthma
16. Zafirlukast: The first leukotriene-receptor antagonist approved for the treatment of asthma
17. Montelukast for chronic asthma in 6-14 year-old-children
18. Release of leukotrienes in patients with asthma
19. Montelukast added to inhaled beclomethasone in treatment of asthma
20. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A six months randomized multicenter trial
21. Characterization of the human cysteinyl-leukotriene CysLt1 receptor
22. LTB4 concentration in breath condensate collecting during isocapnic hyperventilation in asthmatic children is significant1 increased
23. Effects of montelukast (MK0476), a new potent cysteinyl-leukotriene (LTD4) receptor antagonist, in patints with chronic asthma
24. Effects of montelukast (MK0476), a potent cysteinyl-receptor antagonist, on bronchodilatation in asthmatic subjects treated with and without inhaled corticosteroids
25. Leukotriene E4 elimination and metabolism in normal subjects
26. Detection of nonvolatile macromolecules in breath
27. Effects of six week therapy with oral doses of ICI 204, 219, a leukotriene D4 receptor antagonist, in subjects in bronchial asthma
28. Leukotriene antagonist prevents exacerbation of asthma during reduction of high dose inhaled corticosteroid
29. Gas chromatographic-mass spectrometric determination of leukotriene E4 in human urine using deuterium-labelled leukotriene E4 standards
30. Leukotrienes in breathing condensate released during bronchial challenge test